Additionally, the use of IL-23 inhibitors correlates with a reduced incidence of infections and malignancies in comparison to anti-TNF-α therapy, with significantly reduced risks of certain pathologies, such as encephalitis. This evidence concerns the gene IL37 and encephalitis.